Trial Profile
A Phase 2b, Multicenter, Treatment-Arm Blind, Safety And Efficacy 32-Week Extension Study Of Apremilast (CC-10004) In Subjects Who Completed The Treatment Phase Of The Core Study CC-10004-PSOR-005 [EXTENSION OF 700042305]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2014
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 12 May 2014 New trial record